NEW YORK — Merck & Co on Jan. 13 said it had provided U.S. regulators with new information needed for approval to market its Gardasil cervical cancer vaccine to women between the ages of 27 to 45, Reuters reported.

The CDC's adult immunization guidelines includes a new recommendation that women 19 to 26 be immunized with either the quadrivalent human papillomavirus (HPV) vaccine or the recently approved bivalent HPV vaccine to reduce their risk of cervical cancer.